Skip to main content
NCBI home page
The Journal of Clinical Investigation logoLink to The Journal of Clinical Investigation
. 1987 Sep;80(3):750–757. doi: 10.1172/JCI113130

Hepatic processing of transforming growth factor beta in the rat. Uptake, metabolism, and biliary excretion.

R J Coffey Jr, L J Kost, R M Lyons, H L Moses, N F LaRusso
PMCID: PMC442299  PMID: 3476497

Abstract

Transforming growth factor beta (TGF beta), a recently discovered polypeptide, modulates growth of normal and neoplastic cells. Since little is known concerning in vivo disposition of TGF beta, we performed studies to examine the hepatic processing of biologically active 125I-TGF beta in the rat. After intravenous injection, 125I-TGF beta disappeared from the plasma with an initial t1/2 of 2.2 min; partial hepatectomy delayed the plasma disappearance of 125I-TGF beta by 80%. 60 min after intrafemoral injection, 63% of the recovered label was present in liver and/or bile; by 90 min, most of the label removed by the liver (83%) had been slowly excreted into bile. Nearly all the label in bile (96%) was soluble in trichloracetic acid and not immunoprecipitable by specific antiserum. Colchicine and vinblastine inhibited cumulative biliary excretion of label by 28 and 37%, respectively; chloroquine and leupeptin each increased the amount of label in bile that was precipitable by trichloracetic acid and that coeluted with authentic 125I-TGF beta on molecular sieve chromatography. There was efficient first-pass hepatic extraction of 125I-TGF beta (36%) in the isolated perfused rat liver, which was inhibited by unlabeled TGF beta (but not by epidermal growth factor, EGF) and by lectins in a dose-dependent manner; prolonged fasting also decreased clearance (26%). After fractionation of liver by differential or isopycnic centrifugation, radiolabel codistributed with marker enzymes for lysosomes. The results indicate rapid, extensive, inhibitable, and organ-selective extraction of TGF beta by the liver. After extraction, TGF beta undergoes efficient transhepatic transport, extensive intracellular metabolism, and slow but complete biliary excretion of its metabolites. Liver fractionation studies and pharmacologic manipulations suggest that these processes are associated with organelles that include microtubules and lysosomes. The data suggest that the liver is a major target tissue or site of metabolism for biologically active TGF beta.

Full text

PDF
750

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Assoian R. K., Komoriya A., Meyers C. A., Miller D. M., Sporn M. B. Transforming growth factor-beta in human platelets. Identification of a major storage site, purification, and characterization. J Biol Chem. 1983 Jun 10;258(11):7155–7160. [PubMed] [Google Scholar]
  2. Burwen S. J., Barker M. E., Goldman I. S., Hradek G. T., Raper S. E., Jones A. L. Transport of epidermal growth factor by rat liver: evidence for a nonlysosomal pathway. J Cell Biol. 1984 Oct;99(4 Pt 1):1259–1265. doi: 10.1083/jcb.99.4.1259. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Carr B. I., Hayashi I., Branum E. L., Moses H. L. Inhibition of DNA synthesis in rat hepatocytes by platelet-derived type beta transforming growth factor. Cancer Res. 1986 May;46(5):2330–2334. [PubMed] [Google Scholar]
  4. Childs C. B., Proper J. A., Tucker R. F., Moses H. L. Serum contains a platelet-derived transforming growth factor. Proc Natl Acad Sci U S A. 1982 Sep;79(17):5312–5316. doi: 10.1073/pnas.79.17.5312. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Cuatrecasas P. Interaction of concanavalin A and wheat germ agglutinin with the insulin receptor of fat cells and liver. J Biol Chem. 1973 May 25;248(10):3528–3534. [PubMed] [Google Scholar]
  6. Derynck R., Jarrett J. A., Chen E. Y., Eaton D. H., Bell J. R., Assoian R. K., Roberts A. B., Sporn M. B., Goeddel D. V. Human transforming growth factor-beta complementary DNA sequence and expression in normal and transformed cells. Nature. 1985 Aug 22;316(6030):701–705. doi: 10.1038/316701a0. [DOI] [PubMed] [Google Scholar]
  7. Dunn W. A., LaBadie J. H., Aronson N. N., Jr Inhibition of 125I-asialofetuin catabolism by leupeptin in the perfused rat liver and in vivo. J Biol Chem. 1979 May 25;254(10):4191–4196. [PubMed] [Google Scholar]
  8. Freidenberg G. R., Klein H. H., Kladde M. P., Cordera R., Olefsky J. M. Regulation of epidermal growth factor receptor number and phosphorylation by fasting in rat liver. J Biol Chem. 1986 Jan 15;261(2):752–757. [PubMed] [Google Scholar]
  9. Goldman I. S., Jones A. L., Hradek G. T., Huling S. Hepatocyte handling of immunoglobulin A in the rat: the role of microtubules. Gastroenterology. 1983 Jul;85(1):130–140. [PubMed] [Google Scholar]
  10. Gores G. J., Kost L. J., LaRusso N. F. The isolated perfused rat liver: conceptual and practical considerations. Hepatology. 1986 May-Jun;6(3):511–517. doi: 10.1002/hep.1840060331. [DOI] [PubMed] [Google Scholar]
  11. Gores G. J., LaRusso N. F., Miller L. J. Hepatic processing of cholecystokinin peptides. I. Structural specificity and mechanism of hepatic extraction. Am J Physiol. 1986 Mar;250(3 Pt 1):G344–G349. doi: 10.1152/ajpgi.1986.250.3.G344. [DOI] [PubMed] [Google Scholar]
  12. Gores G. J., Miller L. J., LaRusso N. F. Hepatic processing of cholecystokinin peptides. II. Cellular metabolism, transport, and biliary excretion. Am J Physiol. 1986 Mar;250(3 Pt 1):G350–G356. doi: 10.1152/ajpgi.1986.250.3.G350. [DOI] [PubMed] [Google Scholar]
  13. LaRusso N. F., Fowler S. Coordinate secretion of acid hydrolases in rat bile. J Clin Invest. 1979 Oct;64(4):948–954. doi: 10.1172/JCI109561. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. LaRusso N. F., Kost L. J., Carter J. A., Barham S. S. Triton WR-1339, a lysosomotropic compound, is excreted into bile and alters the biliary excretion of lysosomal enzymes and lipids. Hepatology. 1982 Mar-Apr;2(2):209–215. doi: 10.1002/hep.1840020204. [DOI] [PubMed] [Google Scholar]
  15. LaRusso N. F. Proteins in bile: how they get there and what they do. Am J Physiol. 1984 Sep;247(3 Pt 1):G199–G205. doi: 10.1152/ajpgi.1984.247.3.G199. [DOI] [PubMed] [Google Scholar]
  16. Lake J. R., Licko V., Van Dyke R. W., Scharschmidt B. F. Biliary secretion of fluid-phase markers by the isolated perfused rat liver. Role of transcellular vesicular transport. J Clin Invest. 1985 Aug;76(2):676–684. doi: 10.1172/JCI112021. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Lawrence D. A., Pircher R., Jullien P. Conversion of a high molecular weight latent beta-TGF from chicken embryo fibroblasts into a low molecular weight active beta-TGF under acidic conditions. Biochem Biophys Res Commun. 1985 Dec 31;133(3):1026–1034. doi: 10.1016/0006-291x(85)91239-2. [DOI] [PubMed] [Google Scholar]
  18. LeSage G. D., Kost L. J., Barham S. S., LaRusso N. F. Biliary excretion of iron from hepatocyte lysosomes in the rat. A major excretory pathway in experimental iron overload. J Clin Invest. 1986 Jan;77(1):90–97. doi: 10.1172/JCI112307. [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. Leof E. B., Proper J. A., Goustin A. S., Shipley G. D., DiCorleto P. E., Moses H. L. Induction of c-sis mRNA and activity similar to platelet-derived growth factor by transforming growth factor beta: a proposed model for indirect mitogenesis involving autocrine activity. Proc Natl Acad Sci U S A. 1986 Apr;83(8):2453–2457. doi: 10.1073/pnas.83.8.2453. [DOI] [PMC free article] [PubMed] [Google Scholar]
  20. Massagué J. Subunit structure of a high-affinity receptor for type beta-transforming growth factor. Evidence for a disulfide-linked glycosylated receptor complex. J Biol Chem. 1985 Jun 10;260(11):7059–7066. [PubMed] [Google Scholar]
  21. Moses H. L., Branum E. L., Proper J. A., Robinson R. A. Transforming growth factor production by chemically transformed cells. Cancer Res. 1981 Jul;41(7):2842–2848. [PubMed] [Google Scholar]
  22. Roberts A. B., Anzano M. A., Lamb L. C., Smith J. M., Sporn M. B. New class of transforming growth factors potentiated by epidermal growth factor: isolation from non-neoplastic tissues. Proc Natl Acad Sci U S A. 1981 Sep;78(9):5339–5343. doi: 10.1073/pnas.78.9.5339. [DOI] [PMC free article] [PubMed] [Google Scholar]
  23. Roberts A. B., Frolik C. A., Anzano M. A., Sporn M. B. Transforming growth factors from neoplastic and nonneoplastic tissues. Fed Proc. 1983 Jun;42(9):2621–2626. [PubMed] [Google Scholar]
  24. Robinson R. A., Volkenant M. E., Ryan R. J., Moses H. L. Decreased epidermal growth factor binding in cells growth arrested in G1 by nutrient deficiency. J Cell Physiol. 1981 Dec;109(3):517–524. doi: 10.1002/jcp.1041090318. [DOI] [PubMed] [Google Scholar]
  25. Savage C. R., Jr, Cohen S. Epidermal growth factor and a new derivative. Rapid isolation procedures and biological and chemical characterization. J Biol Chem. 1972 Dec 10;247(23):7609–7611. [PubMed] [Google Scholar]
  26. Schiff J. M., Fisher M. M., Underdown B. J. Receptor-mediated biliary transport of immunoglobulin A and asialoglycoprotein: sorting and missorting of ligands revealed by two radiolabeling methods. J Cell Biol. 1984 Jan;98(1):79–89. doi: 10.1083/jcb.98.1.79. [DOI] [PMC free article] [PubMed] [Google Scholar]
  27. Sewell R. B., Barham S. S., LaRusso N. F. Effect of chloroquine on the form and function of hepatocyte lysosomes. Morphologic modifications and physiologic alterations related to the biliary excretion of lipids and proteins. Gastroenterology. 1983 Nov;85(5):1146–1153. [PubMed] [Google Scholar]
  28. Shipley G. D., Childs C. B., Volkenant M. E., Moses H. L. Differential effects of epidermal growth factor, transforming growth factor, and insulin on DNA and protein synthesis and morphology in serum-free cultures of AKR-2B cells. Cancer Res. 1984 Feb;44(2):710–716. [PubMed] [Google Scholar]
  29. Shipley G. D., Pittelkow M. R., Wille J. J., Jr, Scott R. E., Moses H. L. Reversible inhibition of normal human prokeratinocyte proliferation by type beta transforming growth factor-growth inhibitor in serum-free medium. Cancer Res. 1986 Apr;46(4 Pt 2):2068–2071. [PubMed] [Google Scholar]
  30. St Hilaire R. J., Hradek G. T., Jones A. L. Hepatic sequestration and biliary secretion of epidermal growth factor: evidence for a high-capacity uptake system. Proc Natl Acad Sci U S A. 1983 Jun;80(12):3797–3801. doi: 10.1073/pnas.80.12.3797. [DOI] [PMC free article] [PubMed] [Google Scholar]
  31. Thomas P., Toth C. A., Zamcheck N. The mechanism of biliary excretion of alpha 1-acid glycoprotein in the rat: evidence for a molecular weight-dependent, nonreceptor-mediated pathway. Hepatology. 1982 Nov-Dec;2(6):800–803. doi: 10.1002/hep.1840020610. [DOI] [PubMed] [Google Scholar]
  32. Tucker R. F., Branum E. L., Shipley G. D., Ryan R. J., Moses H. L. Specific binding to cultured cells of 125I-labeled type beta transforming growth factor from human platelets. Proc Natl Acad Sci U S A. 1984 Nov;81(21):6757–6761. doi: 10.1073/pnas.81.21.6757. [DOI] [PMC free article] [PubMed] [Google Scholar]
  33. Tucker R. F., Shipley G. D., Moses H. L., Holley R. W. Growth inhibitor from BSC-1 cells closely related to platelet type beta transforming growth factor. Science. 1984 Nov 9;226(4675):705–707. doi: 10.1126/science.6093254. [DOI] [PubMed] [Google Scholar]

Articles from Journal of Clinical Investigation are provided here courtesy of American Society for Clinical Investigation

RESOURCES